
    
      This is a prospective, multi-center, single arm feasibility study to assess the safety and
      performance of the transShield EPS. Patients with severe native aortic valve stenosis
      scheduled for TAVR will be screened for study eligibility. Subjects who meet the commercially
      approved indications for TAVR and comply with the study inclusion/exclusion criteria are
      eligible for enrollment. Patients will be followed for 30 days post procedure.
    
  